ScanGlean
Take the Fit Check Fit Check

Blog

Can Preventive Scans or Longevity Clinics Actually Prevent Heart Attacks?

ScanGlean Editorial Team · July 24, 2026 · 24 min read

Here’s a scenario that plays out often enough to have its own body of research behind it: someone in their 40s or 50s, who feels completely fine, pays several thousand dollars for a longevity clinic membership or an executive physical. They get scanned head to toe. The report comes back clean, or close to it. They walk out feeling like they’ve bought themselves a receipt of good health — and then, months or years later, they have a heart attack anyway, sometimes a fatal one, with no warning at all.

It sounds like a contradiction. It isn’t, once you understand what most of these scans are actually looking at. Heart disease is the leading cause of death worldwide, and unlike most cancers, a huge share of it announces itself for the very first time as the event itself — a heart attack or sudden cardiac death — rather than as a symptom you’d notice beforehand. That single fact is why “can a scan stop this” is such a loaded, high-stakes question, and why it deserves a more careful answer than either a longevity clinic’s sales page or a cynic’s dismissal of the whole industry.

The honest answer has two halves that are both true at once: some of what’s being sold genuinely works and is backed by real trial data, and the single most popular “preventive scan” product on the market — the full-body MRI — doesn’t examine your heart’s arteries at all. Untangling which is which is the point of this article.

Key takeaways

  • Scans don’t prevent heart attacks by themselves. Only the treatment decision that follows a scan — a statin, a lifestyle change, sometimes a procedure — actually lowers your risk. A scan that changes nothing changes nothing.
  • Full-body MRI, the flagship test at most longevity clinics, cannot measure coronary artery calcium and cannot reliably assess your coronary arteries at all. A “clean” full-body MRI tells you nothing about your heart attack risk.
  • Coronary artery calcium (CAC) scoring is genuinely well-validated for refining individual risk and guiding statin decisions — but no randomized trial has yet proven that screening people with no symptoms using CAC, and treating based on the result, reduces heart attacks at a population level. That’s an open, actively-studied question, not settled science.
  • The strongest real-world evidence that “scan, then treat” reduces heart attacks and cardiac deaths comes from SCOT-HEART, a 10-year randomized trial — but it studied people who already had chest pain, not healthy people with no symptoms.
  • Roughly half of men and nearly two-thirds of women who die suddenly from coronary heart disease had no previously recognized symptoms — which is exactly the gap CAC scoring and Lp(a) testing exist to close.
  • Lp(a), a largely genetic and often-skipped cholesterol marker, is now recommended for one-time testing in every adult by the 2024 National Lipid Association and 2025 ESC/EAS guidelines, yet remains one of the most underused tests in cardiology.

Quick Answer: What Actually Predicts Heart Attack Risk, by Test

Test What it actually measures Evidence strength Who it’s for
Coronary artery calcium (CAC) score Calcified (hardened) plaque only Strong for individual risk refinement; guideline-recommended for statin decisions. No outcome trial yet proves screening asymptomatic people reduces heart attacks Adults ~40–75 with borderline-to-intermediate risk
Coronary CT angiography (CCTA) Both calcified and soft, non-calcified plaque, plus narrowing Strong — the only cardiac imaging test with a 10-year randomized trial showing fewer heart attacks and cardiac deaths People with chest pain or symptoms; increasingly, high-risk asymptomatic people after an elevated CAC score
Lipoprotein(a), Lp(a) blood test A genetically-determined, LDL-independent risk particle Strong association evidence; now guideline-recommended as a one-time test for every adult Everyone, once in a lifetime
ApoB / advanced lipid panel Number of atherogenic (artery-clogging) particles, not just cholesterol amount Strong — considered by many cardiologists a better predictor than standard LDL Anyone getting cholesterol checked, especially with a family history
Full-body MRI Soft tissue, organs, some vascular structures — not coronary artery plaque or calcium Not designed for coronary artery assessment at all Not a cardiac risk test, regardless of marketing
Standard risk calculators (Pooled Cohort Equations, Framingham) Statistical estimate from age, cholesterol, blood pressure, smoking status Reasonable population-level tool but frequently mis-ranks individuals; CAC reclassifies close to half of people initially labeled “intermediate risk” Everyone, as a starting point, not an ending point

Not sure which of these applies to you? Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers, graded against major cardiology and USPSTF guidelines. Take the Fit Check →

Why This Question Actually Matters

Cardiovascular disease kills more people than any other cause, and the reason preventive scanning is such an emotionally loaded topic here — more than it is for, say, a skin check — is this: for a huge share of people, the first sign of heart disease is a heart attack. Not chest tightness on a walk. Not a warning trip to urgent care. The event itself.

The data behind that is stark. Among people who die suddenly from coronary heart disease, roughly half of men and closer to two-thirds of women had no previously recognized symptoms of heart disease at all. Separately, researchers estimate about 1 in 5 heart attacks are “silent” — detectable later on an EKG or scan, but never registered by the person as a heart attack while it was happening. And then there’s the one almost everyone has heard of by name but few understand medically: the “widowmaker,” a complete blockage of the left anterior descending artery, which alone feeds nearly half the heart muscle’s blood supply. Because the territory at risk is so large, a full blockage there can cause severe damage within minutes, and it’s disproportionately likely to strike someone with no prior diagnosis.

Put those three facts together and you get the real appeal of preventive cardiac scanning — not vague anti-aging optimization, but a genuine, well-founded fear of being one of the people whose warning system simply doesn’t go off before the event that matters. That’s a completely reasonable thing to want to protect against. The question is which tools actually do it.

The Blind Spot Nobody Tells You About

If you’ve looked into longevity clinics or “preventive scan” packages, you’ve almost certainly come across full-body MRI, sold by companies like Prenuvo, Ezra, and others, and increasingly bundled into premium executive physicals. It’s marketed with sweeping language about catching disease “anywhere in the body” — and to be fair, it can pick up real findings in organs, soft tissue, and some blood vessels.

What it cannot do is look at your coronary arteries in any clinically useful way. Calcium — the exact substance a CAC scan is built to measure — doesn’t show up on MRI the way it does on CT, and the coronary arteries themselves are small, constantly moving with every heartbeat, and require a completely different imaging approach (gated CT, timed to the cardiac cycle) to resolve clearly. A radiology report from a full-body MRI provider will typically note the heart’s general size and structure, maybe flag a major structural abnormality if one exists — but it is not evaluating whether your arteries are clogging up, because MRI isn’t built to see that.

This matters enormously for how people interpret their own results. A “clean” full-body MRI can create a specific, false sense of security about the exact disease most likely to actually kill the person holding it — because the test never looked. If a heart attack is genuinely what you’re trying to rule out, a full-body MRI is, functionally, the wrong test, no matter how comprehensive its marketing sounds. You’d need to add a dedicated cardiac test on top of it, and most full-body MRI packages don’t include one by default.

What Actually Works — Graded Against the Evidence

Coronary artery calcium (CAC) scoring: the best-validated risk tool most people have never heard of

A CAC scan is a quick, low-dose CT scan — no contrast dye, done in about 10 minutes — that quantifies calcified plaque buildup in your coronary arteries and reports it as a single number called an Agatston score. Zero means no detectable calcified plaque. Scores climb from there, and a score above 400 signals extensive disease.

The evidence behind CAC as an individual risk-refinement tool is genuinely strong, largely thanks to the Multi-Ethnic Study of Atherosclerosis (MESA), a long-running NIH-funded cohort that has followed thousands of adults for decades. CAC scoring consistently outperforms standard risk calculators like the Pooled Cohort Equations at correctly sorting people into the right risk category — reclassifying close to half of people initially labeled “intermediate risk” into either a meaningfully higher or lower category once their actual plaque burden is measured. In cohort data, people with a CAC score between 100 and 399 had roughly a 4-fold higher risk of a heart attack or coronary death within 5 years compared to people with a score of zero, and that risk climbed to roughly 10-fold for scores of 400 or higher. This is exactly why the 2018 ACC/AHA cholesterol guideline gives CAC scoring a formal, named role: for people in the fuzzy middle of the risk spectrum, where it’s genuinely unclear whether a statin is worth starting, a CAC score is recommended to help make that call, one way or the other.

The score of zero deserves its own mention, because it’s become something of a cult concept — the “power of zero” — among CAC enthusiasts. It’s earned, mostly: MESA data shows people with a score of zero have a very low chance of a cardiac event over the following decade or more, sometimes described as a “warranty period.” But it’s not an unconditional pass. The same MESA research program found that smoking, diabetes, and high blood pressure keep independently raising risk even in people who score a flat zero — meaning a 45-year-old smoker with a zero score is not in the same risk category as a 45-year-old non-smoker with a zero score, even though their scan results look identical on paper.

Here’s the honest complication, and the thing that separates careful reporting on this topic from marketing copy: USPSTF, the body that grades US screening tests, currently rates the evidence on CAC scoring for general population screening as insufficient — not “harmful,” not “don’t do it,” but literally not enough data yet to weigh benefits against harms for asymptomatic people as a category. That sits in real tension with the ACC/AHA guideline above, and both things are true simultaneously: CAC is well-validated for refining risk in someone who’s already being evaluated for cardiovascular risk, while remaining unproven, in strict trial terms, as a blanket population screening tool. The trial designed to settle that exact question — ROBINSCA, a Dutch study of over 43,000 adults randomized to CAC-based screening, traditional risk-factor screening, or no screening — is ongoing, with its definitive hard-outcome results (actual heart attacks and deaths prevented) not yet conclusively published as of this writing. That’s not a knock against CAC scoring; it’s a genuinely accurate description of where the science currently stands, and it’s worth knowing before anyone tells you the question is fully settled in either direction.

What CAC misses: soft plaque, and where CCTA and Cleerly come in

CAC scoring has one structural limitation worth understanding clearly: it can only see calcified, hardened plaque. It is blind to soft, non-calcified plaque — and soft plaque is, somewhat counterintuitively, often the more dangerous kind, because it’s more prone to sudden rupture, which is the actual mechanical event that triggers most heart attacks. In theory, someone could have a CAC score of zero and still be carrying a meaningful amount of unstable soft plaque that a calcium scan simply can’t detect.

This is where coronary CT angiography (CCTA) enters the picture. It’s a more involved CT scan, using injected contrast dye to visualize the artery walls directly, which lets it see both calcified and soft plaque, along with the degree of narrowing in each artery. Increasingly, CCTA scans are read with the help of FDA-cleared AI software like Cleerly, now used by several longevity clinics, which automatically quantifies exactly how much of each plaque type is present and how it’s trending — a level of detail that used to require a specialized cardiac radiologist reading the images by eye.

CCTA also happens to carry the single best piece of outcome evidence in this entire article: SCOT-HEART, a randomized controlled trial of over 4,000 people with new chest pain, assigned to either standard care or standard care plus a CCTA scan. At 5 years, the CCTA group had a 41% relative reduction in coronary heart disease death or non-fatal heart attacks. Crucially, the trial’s 10-year follow-up, published in The Lancet in 2024, confirmed the benefit held up over the long run — 6.6% of the CCTA group had died of coronary heart disease or had a non-fatal heart attack, compared to 8.2% in the standard-care group — with the CCTA group also receiving significantly more preventive prescriptions (statins, aspirin) along the way. That last detail matters more than it might seem: it’s the clearest proof in cardiovascular medicine that a scan changing a treatment decision is the actual mechanism by which fewer people had heart attacks, not the scan itself.

The caveat, again, is who was studied: SCOT-HEART enrolled people who already had chest pain, not healthy people with no symptoms getting a scan out of general precaution. CCTA is increasingly used as a next step for asymptomatic people with an elevated CAC score or strong risk factors, but as a first-line test for someone with no symptoms and no elevated risk markers, it isn’t the standard recommendation — CAC scoring, being lower-cost, radiation-lighter, and dye-free, generally is.

Lipoprotein(a): the test almost nobody gets, and almost everyone should

Ask most people what their cholesterol numbers are and they can rattle off LDL and HDL. Ask about Lp(a) and you’ll usually get a blank look — including, often, from their own doctor, since it isn’t part of a routine lipid panel by default.

Lp(a) is a cholesterol-carrying particle whose blood level is determined almost entirely by genetics rather than diet, exercise, or lifestyle, which makes it fundamentally different from LDL. Roughly 1 in 5 people has an elevated level (generally defined as 50 mg/dL or higher), and an elevated Lp(a) independently raises the risk of heart attack, stroke, and aortic valve disease — on top of whatever your LDL number already tells you. Because the level is genetically fixed, it typically only needs to be checked once in a lifetime, which is exactly the recommendation made by the 2024 National Lipid Association guideline and echoed by the 2025 ESC/EAS cardiology guidelines: test every adult at least once.

Despite that, real-world testing data shows Lp(a) remains dramatically underused in routine practice, even in patients who already have known cardiovascular disease. For someone assembling a genuinely useful cardiac risk picture, Lp(a) is arguably the single highest-value, lowest-effort addition available — a one-time blood draw that most standard checkups simply never think to order.

So — Can a Scan Actually Prevent a Heart Attack?

Strictly speaking, no. A scan is a measurement, not a treatment. What prevents a heart attack is what happens after the scan: starting a statin, correcting blood pressure, quitting smoking, adding aspirin in specific high-risk situations, or, in more advanced cases, a procedure to open a severely blocked artery. A perfect scan result that changes nothing about how someone lives or what they take does nothing for their actual risk, no matter how expensive or detailed the imaging was.

That distinction is the entire story of SCOT-HEART’s success: CCTA didn’t lower anyone’s risk by existing. It lowered risk because doctors and patients used the results to prescribe more preventive medication than they otherwise would have, and that changed behavior is what showed up, a decade later, as fewer heart attacks and fewer deaths. The scan was the trigger, not the mechanism.

This is also where the psychology of preventive scanning gets genuinely tricky, and it’s worth naming directly: a scan report feels like an answer, in a way that “here’s your statistical risk based on your age and cholesterol” never quite does. A number on a page — calcium score, Lp(a), a percentage risk — feels concrete and actionable, and that feeling is part of why these tests are valuable, not despite being emotionally compelling but partly because of it. People are measurably more likely to actually start and stay on a statin after seeing their own calcium buildup in a picture than after being told an abstract risk percentage. That’s a real, useful psychological lever — but it only works if the number leads somewhere. A calcium score sitting unopened in a patient portal, or a full-body MRI report that never even looked at the heart in the first place, provides that same feeling of having “done something,” without any of the downstream protection.

What Longevity Clinics Actually Add on the Cardiac Side

To their credit, the more clinically serious longevity clinics have generally gotten this part right, even where their broader marketing overreaches elsewhere. Programs like Fountain Life’s higher tiers and Human Longevity’s Health Nucleus pair full-body MRI with CCTA (often Cleerly-read) or a dedicated coronary calcium score, plus an Lp(a) and ApoB-inclusive lipid panel — which is, on the cardiac side specifically, a genuinely well-assembled panel of real, validated tests, not filler. We’ve broken down exactly what’s included and what it costs at each major clinic in our full longevity clinics comparison.

The honest question isn’t whether these individual tests work — mostly, they do. It’s whether a $10,000-to-$25,000 annual membership is the only way to access them. It generally isn’t: a CAC score can be self-pay ordered for $100 to $150 at most imaging centers without a longevity clinic membership, Lp(a) and ApoB are standard blood draws any physician can order, and CCTA is available through any hospital or cardiology practice when clinically indicated. What a longevity clinic membership actually buys, on the cardiac side, is convenience, bundling, and often a Cleerly-style AI read layered on top — real value for people who can afford it, but not the only route to the underlying tests themselves. We cover this gap between “the tests are real” and “you need this specific membership to get them” in more detail in our guide to executive health programs and our breakdown of full-body MRI providers, including exactly why full-body MRI shouldn’t be anyone’s only cardiac test.

Who Should Actually Get What

A reasonable, evidence-aligned starting point looks roughly like this: everyone gets standard risk-factor screening (blood pressure, a lipid panel, diabetes screening) as the baseline, which is well-established and inexpensive. If you’re in your 40s to 70s and your calculated risk lands in a borderline or intermediate zone — not clearly low, not clearly high — a CAC score is a strong, well-evidenced next step to get a real number instead of a population-level guess. Everyone, once, benefits from an Lp(a) test, since it’s a single blood draw that meaningfully sharpens the picture and rarely gets ordered by default. If you have chest pain, shortness of breath on exertion, or other symptoms, or if your CAC score comes back elevated, CCTA is the logical next step, ideally at a center that can offer AI-assisted plaque analysis. And if what you actually want is reassurance specifically about your heart’s arteries, a full-body MRI is not that test, regardless of how it’s marketed — it’s a different tool, for a different job.

The Bottom Line

Preventive cardiac scanning isn’t a myth, and it isn’t a scam — but it also isn’t one single thing, and the specific test matters enormously more than the marketing implies. Coronary artery calcium scoring is a real, guideline-recommended tool for refining individual risk, even though it hasn’t yet been proven in a population-screening trial to reduce heart attacks outright. Coronary CT angiography has the best hard-outcome trial evidence of any cardiac imaging test available, in the population it’s actually been studied in. Lp(a) is a cheap, one-time blood test that’s wildly underused relative to how much it actually tells you. And full-body MRI — the test most people picture when they hear “preventive scan” — doesn’t examine your heart’s arteries at all, making it the wrong answer to the exact question this article opened with. None of these tools prevent a heart attack by sitting in a folder. What prevents a heart attack is what a person and their doctor decide to do once they know the real number — which makes the most important question not “which scan should I buy,” but “which of these results will I actually act on.”

Frequently Asked Questions

Can preventive scans actually prevent heart attacks?

Not by themselves. A scan can only show you your risk — it’s the medication, lifestyle change, or procedure that follows it that actually lowers your odds of a heart attack. The best evidence for this full chain (scan → changed treatment → fewer heart attacks) comes from SCOT-HEART, a randomized trial in people with chest pain, where CT angiography led to more preventive prescriptions and, a decade later, measurably fewer heart attacks and cardiac deaths. For people with no symptoms at all, the picture is genuinely weaker: coronary artery calcium scoring is well-validated for estimating risk, but no trial has yet proven that screening asymptomatic people with it, and then treating based on the result, reduces heart attacks at a population level.

What is a coronary artery calcium (CAC) score, and is it worth getting?

A CAC score is a low-dose CT scan that measures calcified plaque in your heart’s arteries, producing a number from 0 upward (over 400 signals extensive disease). It’s genuinely one of the best-validated tools in preventive cardiology for reclassifying risk — the 2018 ACC/AHA cholesterol guideline recommends it to help decide whether a borderline-risk person should start a statin. It’s worth getting if you’re in your 40s to 70s with borderline or intermediate cardiovascular risk and want a real number instead of a guess. It’s not a general population screening test — USPSTF says the evidence is still insufficient to recommend it for everyone, mainly because no trial has yet proven CAC-guided screening reduces heart attacks compared to standard risk-factor assessment alone.

Does a full-body MRI check for heart attack risk?

No — and this is the single most misunderstood fact about full-body MRI scans sold by longevity clinics like Prenuvo. MRI cannot measure coronary artery calcium and cannot reliably visualize the small, constantly moving arteries that wrap around the heart. If heart attack risk is what you’re actually worried about, a full-body MRI report coming back “clean” tells you nothing about your coronary arteries — you need a dedicated coronary calcium scan or CT angiogram, which is a completely different test.

What does a CAC score of zero mean?

It’s a strong, genuinely reassuring signal — often called the “power of zero.” Data from the Multi-Ethnic Study of Atherosclerosis (MESA) shows people with a CAC score of zero have a very low risk of a heart attack over the following 10 to 15 years. But zero isn’t a permanent hall pass: MESA researchers also found that smoking, diabetes, and high blood pressure still independently raise risk even in people who score a zero, and the protective “warranty period” is shorter for people with those risk factors.

What is Lp(a) and why does almost nobody get it tested?

Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle whose level is almost entirely set by your genes, not your diet or exercise habits — which is exactly why standard checkups tend to skip it. About 1 in 5 people has an elevated level, and it raises heart attack and stroke risk independently of LDL cholesterol. The 2024 National Lipid Association and 2025 ESC/EAS guidelines both now recommend testing every adult at least once in their life, since a single blood draw is enough — the number doesn’t meaningfully change over time the way LDL does.

Is coronary CT angiography (CCTA) better than a calcium score?

They answer different questions. A calcium score counts hardened, calcified plaque but completely misses soft, non-calcified plaque — which is actually the type more likely to rupture and cause a sudden heart attack. CCTA is a more detailed CT scan (with contrast dye) that can see both plaque types, and AI software like Cleerly can then quantify how much of each is present. CCTA is also the test with real randomized-trial evidence behind it: in SCOT-HEART, using CCTA to guide treatment in people with chest pain led to fewer heart attacks and cardiac deaths a decade later. It’s typically used for people with symptoms or an already-elevated calcium score, not as a first-line test for everyone.

What is a “widowmaker” heart attack?

It’s the nickname for a complete blockage of the left anterior descending (LAD) artery, which alone supplies close to half the blood flow to the heart muscle. Because the affected territory is so large, a full blockage there can cause severe, fast-moving damage — the medical name is an anterior STEMI. It’s called a widowmaker because of how quickly it can be fatal, especially in someone who has never had symptoms before, which is exactly the scenario coronary calcium scoring and Lp(a) testing are designed to catch in advance.

How much does a coronary calcium scan cost, and is it covered by insurance?

Self-pay pricing typically runs $100 to $150 at imaging centers running promotions, and up to $250–$400 at hospitals or in major cities, according to 2025–2026 pricing data. Many insurers don’t cover it as a pure screening test in someone with no symptoms, since USPSTF hasn’t issued a positive screening recommendation — though it’s HSA/FSA-eligible, and coverage varies by plan and by whether your doctor documents a specific risk-based reason for ordering it. The radiation dose is low, roughly 1.0 to 1.5 mSv, about the equivalent of 10 to 15 chest X-rays.

This article is for general educational and informational purposes only. It is not medical advice, and it is not a substitute for diagnosis, treatment, or guidance from a licensed physician or other qualified healthcare provider. Whether any cardiac test is appropriate for you depends on your individual age, risk factors, family history, and symptoms — always consult a clinician before making decisions about cardiovascular screening or your health. See our Methodology page for how we research and grade the evidence behind claims like these.

Sources

← Back to all guides

Newsletter

Before you go — get new comparisons first.

One email when we publish a new provider comparison, cost guide, or evidence review. No spam, no clinic promotions.